Skip to content

Rebecca Matthews

5 papers in the library · 1,267 citations · publishing 2021-2023

Papers

Sort Most recent Most cited

MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.

FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 97 citations

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...

Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder

Journal of Humanistic Psychology June 23, 2021 Julie B. Wang, Jessica Lin, Leah Bedrosian et al. 22 citations

Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized...

DOI: 10.1177/00221678211023663 (opens in new tab) Psychedelic therapy PTSD Treatment Trauma therapy Mental health treatment +15

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.

Nature Medicine June 1, 2021 Jennifer Mitchell, Michael P. Bogenschutz, Alia Lilienstein et al. 965 citations

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with...

DOI: 10.1038/s41591-021-01336-3 (opens in new tab) Full text (opens in new tab) PTSD Treatment MDMA Therapy Clinical trials Mental health breakthrough

The short-term impact of 3 smoked cannabis preparations versus placebo on PTSD symptoms: A randomized cross-over clinical trial

PLoS One March 17, 2021 Marcel O Bonn-Miller, Sue Sisley, Paula Riggs et al. 129 citations

IMPORTANCE: There is a pressing need for development of novel pharmacology for the treatment of Posttraumatic Stress Disorder (PTSD). Given increasing use of medical cannabis among US military veterans to self-treat PTSD, there is strong public interest in whether cannabis may be a safe and effective treatment for PTSD. OBJECTIVE: The aim of the present study was to collect preliminary data on...

DOI: 10.1371/journal.pone.0246990 (opens in new tab) Cannabis Placebo Randomized controlled trial Pathology +1

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for victims of sexual abuse with severe post-traumatic stress disorder: an open label pilot study in Brazil.

Revista Brasileira de Psiquiatria 2021 Alvaro V Jardim, Dora V Jardim, Bruno Rasmussen Chaves et al. 54 citations

To conduct Brazil's first clinical trial employing 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder (PTSD), given its high prevalence resulting from epidemic violence. Of 60 volunteers, four matched the inclusion & exclusion criteria. Three patients with PTSD secondary to sexual abuse (diagnosed by the Structured Clinical Interview for DSM-IV...